Details

<p>Preface xv</p> <p>Acknowledgments xvii</p> <p><b>Part 1 General Dermatology 1</b></p> <p><b>Common Work-Ups, Signs, and Management 3</b></p> <p>Dermatologic Differential Algorithm 3</p> <p>Direct Immunofluorescence (Dif) 3</p> <p>False positive/negative DIFs 3</p> <p>Workup Quick Reference Orders 4</p> <p>Acne 6</p> <p>Alopecia Workup 7</p> <p>Telogen effluvium 10</p> <p>Androgenic alopecia 10</p> <p>Alopecia areata 11</p> <p>Other alopecia treatments 12</p> <p>Aphthosis Workup and Treatment 13</p> <p>Dermatologic Signs 15</p> <p>Folliculitis 21</p> <p>Melasma 22</p> <p><b>Immunology and Immunologic Disease 24</b></p> <p>Lupus Erythematosus 24</p> <p>Autoantibody 26</p> <p>Sensitivities and specificities 26</p> <p>In connective tissue diseases 28</p> <p>Anti‐nuclear antibodies 29</p> <p>ANCA (Anti‐neutrophil cytoplasmic antibodies) 30</p> <p>Treatment of ANCA‐associated vasculitis 30</p> <p>Vasculitis 31</p> <p>Small vessel vasculitis 31</p> <p>Medium vessel vasculitis 33</p> <p>Large vessel vasculitis 34</p> <p>Cryoglobulinemia 34</p> <p>Bullous Disorders 36</p> <p>Intracorneal/subcorneal 36</p> <p>Intraepidermal 36</p> <p>Suprabasilar 37</p> <p>Subepidermal with little inflammation 37</p> <p>Epidermolysis bullosa 39</p> <p>Major bullous diseases – clinicopathologic findings 42</p> <p>Complement 46</p> <p>Angioedema and complement levels 46</p> <p>Complement deficiencies 47</p> <p>GVHD 47</p> <p>HLA associations 48</p> <p>Th profiles 50</p> <p><b>Special Sites: Glands, Nail, Bone, Mucosa 51</b></p> <p>Glands 51</p> <p>Nail terminology 53</p> <p>Disorders or drugs associated with nail, Bone, or ocular findings 57</p> <p>Genital ulcers 67</p> <p><b>Infection and Infestations 68</b></p> <p>Fungal Disease / Mycoses 68</p> <p>Laboratory tests 68</p> <p>Superficial mycoses 68</p> <p>Cutaneous mycoses 69</p> <p>Subcutaneous mycoses 71</p> <p>Systemic mycoses 73</p> <p>Opportunistic mycoses 75</p> <p>Viruses and diseases 78</p> <p>Human papilloma virus 79</p> <p>Other viral diseases 80</p> <p>Infections/Bugs 83</p> <p>Vector‐borne diseases 83</p> <p>Creatures in dermatology 88</p> <p><b>Contact and Plant Dermatitis 93</b></p> <p>Patch testing 93</p> <p>Common contact allergens 95</p> <p>Allergic vs. irritant contact dermatitis 104</p> <p>Allergens – location specific 105</p> <p>Features suggestive of specific irritant/toxin 106</p> <p>Plants and Dermatoses 106</p> <p><b>Tumors and Infiltrates 109</b></p> <p>Cutaneous T Cell Lyphoma 109</p> <p>Cutaneous B‐cell lymphoma 113</p> <p>Leukemia cutis 113</p> <p>Monoclonal Gammopathies in Dermatology 114</p> <p>Tumors and gene associations 115</p> <p><i>For Melanoma, BCC, and SCC, see Skin Cancer</i> 221</p> <p><b>Systemic and Metabolic Diseases 117</b></p> <p>Amyloidoses 117</p> <p>Histiocytosis 119</p> <p>Xanthomas 124</p> <p>Hyperlipoproteinemias 125</p> <p>Vitamin Deficiencies/Hypervitaminoses 127</p> <p><b>Pediatric and Pregnancy Dermatology 131</b></p> <p>Vascular tumors and malformation 131</p> <p>Infantile Hemangioma (IH) Management 132</p> <p>Neonatal vesiculopustular eruptions 137</p> <p>Genodermatoses 142</p> <p>Chromosome abnormalities 171</p> <p>Disorders of cornification 171</p> <p>Disorders of connective tissue 175</p> <p>Ehlers–Danlos 177</p> <p>Collagen types 178</p> <p>Disorder of hair, Nail, ectoderm 179</p> <p>Tumor syndromes 185</p> <p>Disorders of vascularization 186</p> <p>Disorders of metabolism 189</p> <p>Porphyrias 191</p> <p>Disorders of pigmentation 193</p> <p>Immunodeficiency syndromes 196</p> <p>Miscellaneous 198</p> <p>Dermatoses of pregnancy 200</p> <p><b>Dermoscopy and Dermatopathology 202</b></p> <p>Dermoscopy 202</p> <p>Dermatopathology 206</p> <p>Histochemical staining 206</p> <p>Immunohistochemical staining 207</p> <p>Pathologic bodies 210</p> <p>Cysts 214</p> <p>Other derm path buzzwords, Patterns, DDx 215</p> <p><b>Part 2 Surgical and Cosmetic Dermatology 219</b></p> <p><b>Surgical Dermatology 221</b></p> <p>Skin cancer 221</p> <p>Surgical margin guidelines 221</p> <p>Indication for Mohs micrographic surgery 222</p> <p>Melanoma 223</p> <p>Squamous cell carcinoma (SCC) 228</p> <p>Prophylactic antibiotics and antivirals 230</p> <p>Guideline for Prophylactic antibiotics 230</p> <p>Algorithm for antibiotic prophylaxis 231</p> <p>Guideline for prophylactic antivirals 231</p> <p>Antiseptic scrubs 232</p> <p>Anesthetics 234</p> <p>Dose calculation 234</p> <p>Standard formula for buffered Lidocaine 234</p> <p>Tumescent anesthesia 234</p> <p>Topical anesthetic (see drug section pg. 316) 235</p> <p>Adverse reaction to local anesthetics 235</p> <p>Local anesthetic 236</p> <p>Nerve blocks 237</p> <p>Surgical anatomy 237</p> <p>Anatomy of the face 237</p> <p>Danger zones in surgery 242</p> <p>Dermatomal distribution of sensory nerves 244</p> <p>Anatomy of the lower extremity venous system 245</p> <p>Anatomy of the nail 246</p> <p>Cutaneous reconstruction 247</p> <p>Undermining depths in reconstruction 248</p> <p>Reconstruction algorithm: STAIRS 248</p> <p>Sutures 260</p> <p>Absorbable 260</p> <p>Nonabsorbable 261</p> <p>Suture removal time 262</p> <p>Electrosurgery 262</p> <p>Wound healing 262</p> <p>Wound dressing 263</p> <p><b>Cosmetic Dermatology 264</b></p> <p>Laser 264</p> <p>Laser fundamentals 264</p> <p>Laser treatment of tattoo pigment 266</p> <p>Photoinduced eye injury 267</p> <p>Laser wavelength depth of penetration and the electromagnetic spectrum 268</p> <p>Absorption spectra of major skin chromophores 268</p> <p>Photodynamic therapy 269</p> <p>Photosensitizer properties and options 269</p> <p>PDT Protocol 270</p> <p>UV spectrum 271</p> <p>UV spectrum and wavelengths 271</p> <p>UVB protection vs SPF 272</p> <p>UV protection measurements 272</p> <p>UV associations/specificities 273</p> <p>Glogau wrinkle scale 273</p> <p>Fitzpatrick skin type 274</p> <p>Chemical peels 274</p> <p>Pre‐peel consideration 274</p> <p>Peeling agents 275</p> <p>Botulinum toxin 277</p> <p>Injectable for adipolysis 280</p> <p>Fillers 281</p> <p>Protocol for vascular occlusion from fillers 288</p> <p>Venous disease treatment 288</p> <p>Vein treatment algorithm 288</p> <p>Sclerotherapy 289</p> <p>Preparing dilution of sclerosants 290</p> <p>CEAP classification for venous disease 292</p> <p>Venous clinical severity score 292</p> <p><b>Part 3 Drugs and Therapies 293</b></p> <p>Medication Quick Reference 295</p> <p>Topical steroids classified by strength 295</p> <p>Nonsteroidals 297</p> <p>Commonly used drugs in dermatology 297</p> <p>Systemic Medications 302</p> <p>Antimalarials 302</p> <p>Immunosuppressive agents 303</p> <p>Systemic retinoids 306</p> <p>Biologics 307</p> <p>General Reference 310</p> <p>Metric measurements 310</p> <p>Dose calculations 310</p> <p>Topical medication dispensing and absorption 310</p> <p>Corticosteroid Dosage Equivalence 311</p> <p>Acne – Topical 311</p> <p>Antibiotics/antimicrobial 311</p> <p>Keratolytics 312</p> <p>Retinoids 313</p> <p>Others 313</p> <p>Acne – Oral 314</p> <p>Antibiotics 314</p> <p>Retinoids 315</p> <p>Others 315</p> <p>Analgesics 315</p> <p>Anesthetics – topical (see also topical anesthetic pg. 235) 316</p> <p>Anesthetics – topical compounded 316</p> <p>Antibiotics 316</p> <p>Topical/antiseptic 316</p> <p>Systemic 317</p> <p>Preoperative prophylaxis see pg. 230</p> <p>Postoperative skin infection 319</p> <p>Sensitivity 321</p> <p>Regimens 322</p> <p>STDs 323</p> <p>Antifungals 324</p> <p>Topical 324</p> <p>Oral 325</p> <p>Antifungal regimens 327</p> <p>Candidal infection 327</p> <p>Pityrosporum folliculitis 327</p> <p>Onychomycosis 327</p> <p>Tinea versicolor (<i>Malassezia</i>) 328</p> <p>Tinea capitis 328</p> <p>Tinea corporis 328</p> <p>Tinea pedis 329</p> <p>Antiparasitics 330</p> <p>Scabies 330</p> <p>Lice 330</p> <p>Antivirals 331</p> <p>HSV 331</p> <p>Herpes zoster/VZV 333</p> <p>Genital warts 333</p> <p>Verruca vulgaris 334</p> <p>Molluscum 334</p> <p>Antihistamines 334</p> <p>Sedating 335</p> <p>Nonsedating 335</p> <p>H2‐blockers 335</p> <p>Antipruritic 336</p> <p>Topical 336</p> <p>Oral 336</p> <p>Anxiolytics/Sedation 338</p> <p>Benzodiazepines 338</p> <p>Antihistamines 339</p> <p>Bleaching Agents/Depigmenting Agents 340</p> <p>Hair 341</p> <p>Alopecia – androgenic 341</p> <p>Alopecia – areata 341</p> <p>Hypertrichosis 342</p> <p>Hypotrichosis – eyelash 342</p> <p>Hyperhidrosis 342</p> <p>Psoriasis 343</p> <p>Topical agents 343</p> <p>Tar 343</p> <p>Anthralin/dithranol 343</p> <p>Systemic agents 343 (see also Systemic Medications pg. 306)</p> <p>Rosacea 344</p> <p>Antibiotics/antimicrobial – topical 344</p> <p>Keratolytics 344</p> <p>Vasoconstrictor 344</p> <p>Other 344</p> <p>Antibiotics – systemic 344</p> <p>Seborrheic Dermatitis 345</p> <p>Skin Cancer – Topical and Oral Chemotherapy 345</p> <p>Actinic keratoses (AK) 345</p> <p>Basal cell carcinoma (BCC) 346</p> <p>CTCL 346</p> <p>Melanoma 347</p> <p>Vasoactive/Antiplatelet Agents 347</p> <p>Vitamins/Nutritional Supplements 348</p> <p>Wound Care 348</p> <p>Miscellaneous Meds 348</p> <p>Cytochrome P‐450 interactions 349</p> <p>Pregnancy Categories of Commonly Used Dermatologic Agents 350</p> <p>Common Dermatologic Drugs and Teratogenic Effects 351</p> <p>Dermatologic Drugs Reportedly Associated with Contraceptive Failure 352</p> <p>Drug Eruptions 352</p> <p>Chemotherapeutic Agents and Skin Changes 355</p> <p>Antidote to extravasation of chemotherapeutic agents 358</p> <p>UV Light Treatment 359</p> <p>UVA/UVB dosing 359</p> <p>NBUVB dosing 359</p> <p>PUVA 359</p> <p>Toxic Epidermal Necrolysis (TEN) Protocol 361</p> <p>Diagnosis of TEN 361</p> <p>Triage algorithm for TEN patients 362</p> <p>Treatment for all TEN patients 363</p> <p>Appendix I American Burn Assocation Burn Center Referral Criteria 364</p> <p>Appendix SCORTEN Score 365</p> <p>Appendix III IVIg 365</p> <p>Appendix IV Further Reading for TEN/SJS 366</p> <p>Index 367</p> <p>Color plate section can be found facing page 208</p>

<p><b>Margaret W. Mann</b> is Associate Professor and Director of Aesthetic Dermatology, University Hospitals, Case Western School of Medicine, Cleveland, OH, USA. She is the Co-Founder of Innova Dermatology, Hendersonville, TN, USA. <p><b>Daniel L. Popkin</b> is<b></b> Assistant Chief of Dermatology, Louis Stokes VA Medical Center and Assistant Professor of Dermatology, University Hospitals, Case Western School of Medicine, Cleveland, OH, USA. He is the Co-Founder of Innova Dermatology, Hendersonville, TN, USA.

<p><b>A comprehensive – yet compact – reference guide for dermatologists in training or in practice</b> <p>The <i>Handbook of Dermatology</i> consolidates the essential information required for best-practice patient care into one pocket-sized volume. This indispensable reference guide enables practicing and prospective dermatologists to easily look up information on a wide range of dermatological diseases and quickly access the algorithms, protocols, guidelines, and staging and scoring systems that are vital to both clinical practice and exam success. Written and edited by former residents and attending physicians, the handbook contains up-to-date information on general dermatology, surgery, and therapeutics. <p>Now in its second edition, this useful guide presents data in outline, bullet-point, and table formats to ensure easy and efficient retrieval. The table of contents and index have been revised and reorganized to allow for faster and more intuitive searches. New material includes a work-up quick reference table, a melasma work-up and management algorithm, information on dermatologic signs and dermoscopy, and more. Updated subject areas include drugs and therapies, fillers and toxins, UV and sunscreen, peeling agents, venous disease, propranolol, and contact dermatitis. <ul> <li>Offers up-to-date information reflecting new gene discoveries and other advancements</li> <li>Updated to cover a range of new medications and treatments, including laser surgery</li> <li>Compact and accessible design for everyday clinical use</li> <li>Features new clinical practice guidelines and algorithms, as well as helpful illustrations and data tables</li> </ul> <p>The <i>Handbook of Dermatology</i> is a valuable resource for trainee and practicing dermatologists, general practitioners, and medical students.

GB